Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosin.
Selected adverse events were evaluated from the combined randomized placebo-controlled clinical trials (once-a-day or twice-a-day; monotherapy or combination therapy) of terazosin in hypertensive patients. The designs of these clinical trials were either titration to response or titration to a fixed dose. A grouped survival methodology using logistic regression, developed by Hosmane et al, was used to study the effects of age and dose on the incidence of adverse events. The analysis indicated that except for palpitations, nausea, headache, and dizziness the incidence of adverse events was not significantly related to either age or dose. Palpitations and headache decreased with increasing age and increasing dose and age, respectively. Dizziness and nausea increased at the maximum dose of 20 mg, but not at the 5- or 10-mg doses.
Hosmane
B S
BS
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064.
Maurath
C J
CJ
Jordan
D C
DC
Laddu
A
A
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D011224:Prazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
C041226:Terazosin; D011224:Prazosin